HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid

HCID 5538
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
78996-15-3
Standard SMILES
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
InChIKey
SHGAZHPCJJPHSC-UHFFFAOYSA-N
Molecular formula
C20H28O2
Average molar mass
300.4 g/mol
Monoisotopic mass
300.20893013

Overview

Retinoic acid is a retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). It has a role as a human metabolite. It is a retinoid and an alpha,beta-unsaturated monocarboxylic acid. It is a conjugate acid of a retinoate.

Names & identifiers

Preferred name
3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
IUPAC
3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
English name
SHGAZHPCJJPHSC-GOWYKSNKSA-N
Molecular formula
C20H28O2
Molecular weight
300.44

Names & synonyms

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acidRefChem:106615311-cis Retinoic Acid3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acidTretinoina (INN-Spanish)Tretinoina [INN-Spanish]Isotretinoin EP Impurity CAvita (0.025% gel)retinylpalmitats1653LGD 100057Spectrum_001676
Show more names
D5-IsotretinoinRetinoic acid-dRetinoic Acid-d5SHGAZHPCJJPHSC-GOWYKSNKSA-NRetinoic-4,4,18,18,18-d5 acidIsotretinoin D5Q: What is Isotretinoin D5 Q: What is the CAS Number of Isotretinoin D5 Q: What is the storage condition of Isotretinoin D5 Q: What are the applications of Isotretinoin D5
SpecPlus_000696Prestwick0_000256Prestwick0_000257Prestwick1_000256Prestwick1_000257Spectrum2_001983Spectrum3_001793Spectrum4_000901

Properties

Computed structural propertiesFilling in

XLogP
6.3
Topological polar surface area
37.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
5
Heavy atoms
22
Formal charge
0
Complexity
567

Experimental & physicochemical properties

LogP6.3

Physicochemical properties

storage temp.
-80 °C · Store at -80°C
solubility
Methanol: Soluble
form
A solid
color
White to off-white

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Exposure Routes1-31% (topical)
Toxicity Summary · 1 item

Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemistry & industry

Pharmacology

Metabolism/MetabolitesHepatic Half Life: 0.5-2 hours

Uses & manufacturing

Uses · 1 item

For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.

Applications · 2 items

Description13-cis Retinoic acid-d5 is intended for use as an internal standard for the quantification of 13-cis retinoic acid by GC- or LC-MS. 13-cis Retinoic acid is a naturally occurring retinoid that inhibits retinol oxidation and dehydrogenation of 17β-hydroxy steroids.

UsesAn endogenous retinoic acid isomer, which is capable of binding to both retinoic acid receptors (RAR) and retinoid X receptors (RXR). A biologically active ligand for members of the RAR and RXR subfamilies, implying that it may play a critical role in regulating retinoid-responsive pathways.

Related reactions

8 records
New reaction record
HRID 140142 reaction equation
HRID 140142As product
HRID 171983 reaction equation
HRID 171983As reactant
HRID 179424 reaction equation
HRID 179424As reactant
HRID 184668 reaction equation
HRID 184668As productAs reactant
HRID 1142109 reaction equation
HRID 1142109As product
HRID 1149157 reaction equation
HRID 1149157As product
HRID 1228653 reaction equation
HRID 1228653As reactant
HRID 1238402 reaction equation
HRID 1238402As productAs reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
78996-15-3
PubChem CID
5538
ChEMBL
CHEMBL1235644
ChEBI
CHEBI:26536